MiKO Pharma Gh., Ltd, a leading force in the pharmaceutical industry, has announced the upcoming ground-breaking ceremony for its new state-of-the-art manufacturing plant, located in the Akosombo-Akwamu Traditional Area.
The ceremony, scheduled for the 1st of October 2024, will be graced by the presence of the President of the Republic of Ghana, Nana Addo Dankwa Akufo-Addo, will officially cut the sod to signify the commencement of construction.
This marks a pivotal moment in MiKO Pharma’s mission to enhance its production capabilities and play a vital role in the socio-economic development of the region.
The ceremony will host a distinguished gathering of government officials, traditional leaders, industry experts, and community members. This groundbreaking symbolizes more than just the start of the project; it demonstrates MiKO Pharma’s significant investment in improving healthcare access and supporting the well-being of Ghanaians and beyond.
Once completed, the new plant will be one of the largest and most advanced pharmaceutical manufacturing facilities in West Africa. The facility will produce essential medications for treating conditions such as high blood pressure, diabetes, heart disease, malaria, and pain management.
Once operational, the plant will substantially increase the availability of affordable, high-quality GMP-compliant pharmaceuticals, thus improving healthcare access and outcomes across the continent.
Beyond healthcare, the project is set to transform the local economy. The construction and operation of the plant are expected to create over 1,000 jobs, many of which will be filled by local residents. The facility will also stimulate local businesses and contribute to the overall economic vitality of the Akosombo-Akwamu area.
Willard Jackson, Executive Partner at MiKO Pharma, highlighted the company’s vision: “This plant is a testament to our commitment to innovation and local empowerment. By investing in Ghana’s pharmaceutical sector, we aim to improve healthcare access, create sustainable jobs, and drive economic growth. This facility marks a significant milestone in our journey toward a healthier, more prosperous future for all.”
MiKO Pharma remains dedicated to sustainability and will incorporate eco-friendly practices throughout the plant’s operations. The facility will feature advanced technology to minimize waste and reduce its carbon footprint, adhering to global sustainability standards in pharmaceutical production.
Key industry partnerships, including collaborations with Siemens and India-based Sushen Medicamentos pvt ltd, support the project.
Sushen Medicamentos pvt ltd brings its expertise in Pharmaceutical Project Management, Formulations, Operations, and Research & Development, ensuring that products manufactured at the new facility meet the highest international
standards.
Currently, 30% of Ghana’s pharmaceutical market is supplied by locally produced drugs, while 70% are imported. The Ghanaian government aims to increase local production over the next decade, a goal that MiKO Pharma shares and actively supports. This new facility will significantly contribute to this objective, bolstering the local pharmaceutical industry and increasing the availability of locally manufactured medicines.
MiKO Pharma also plans to export its products to Europe and the Americas, further establishing Ghana’s presence in the global pharmaceutical market.
READ ALSO:African Leaders Unite For Sustainable Development At UNGA 2024
Dr. Michael K. Obeng, CEO and Founder of MiKO Pharma Gh., Ltd., emphasized the broader vision behind this initiative: “The ground-breaking of our new manufacturing plant is not just a significant step for MiKO Pharma, but for the entire African continent. We aim to produce drugs by Africans, for Africans, and to contribute meaningfully to the global pharmaceutical landscape.
This project is a critical part of our mission to achieve pharmaceutical emancipation
and to promote the well-being of all Africans. I firmly believe that a healthy nation is a wealthy
nation.”
MiKO Pharma Gh. Ltd. warmly invites members of the press and key stakeholders to join in this significant event as the company embarks on this exciting new chapter.
